BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $1,139,964.02 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 31,543 shares of the firm’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $36.14, for a total value of $1,139,964.02. Following the transaction, the chief executive officer now directly owns 211,718 shares of the company’s stock, valued at $7,651,488.52. This represents a 12.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Neil Kumar also recently made the following trade(s):

• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The stock was sold at an average price of $36.29, for a total transaction of $11,864,362.28.

BridgeBio Pharma Stock Up 0.1 %

Shares of BBIO stock opened at $36.85 on Friday. The company has a 50 day moving average price of $31.90 and a 200-day moving average price of $27.93. BridgeBio Pharma, Inc. has a 52 week low of $21.62 and a 52 week high of $39.47. The firm has a market capitalization of $6.96 billion, a PE ratio of -15.29 and a beta of 1.07.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Thursday, February 20th. The company reported ($1.31) EPS for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The business had revenue of $5.88 million for the quarter, compared to analyst estimates of $4.04 million. Analysts anticipate that BridgeBio Pharma, Inc. will post -2.56 earnings per share for the current year.

Institutional Trading of BridgeBio Pharma

A number of hedge funds have recently bought and sold shares of BBIO. Steward Partners Investment Advisory LLC boosted its position in BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after purchasing an additional 472 shares during the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of BridgeBio Pharma in the 4th quarter worth approximately $41,000. Sterling Capital Management LLC boosted its holdings in shares of BridgeBio Pharma by 554.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock worth $49,000 after buying an additional 1,514 shares during the last quarter. Values First Advisors Inc. bought a new stake in BridgeBio Pharma during the third quarter valued at approximately $57,000. Finally, CWM LLC increased its holdings in BridgeBio Pharma by 132.9% during the third quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after buying an additional 1,964 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BBIO. Bank of America upped their price objective on shares of BridgeBio Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, November 25th. HC Wainwright restated a “buy” rating and issued a $49.00 price target on shares of BridgeBio Pharma in a research note on Thursday, February 13th. Citigroup boosted their target price on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday. Evercore ISI raised their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, December 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, BridgeBio Pharma presently has an average rating of “Moderate Buy” and an average target price of $51.67.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.